绝经症状系统性激素治疗的启动与持续模式
基于美国Merative MarketScan数据库2009-2022年数据,纳入318621名45-60岁有绝经相关诊断的女性,分析系统性激素治疗(HT)的启动与持续情况。21.7%在诊断后1年内启动HT,中位首疗程仅6.6个月,12个月持续率38.8%,且存在种族差异。
要点
- 仅21.7%的绝经女性在诊断后1年内启动系统性HT。
- 中位首疗程6.6个月,12个月持续率仅38.8%。
- 黑人和西班牙裔女性停药更快,提示存在差异。
核心结论
- 约五分之一女性在绝经诊断后短期内启动系统性HT,但持续率低且存在种族差异,揭示长期绝经管理存在关键缺口。
研究设计与样本
- 基于Merative MarketScan研究数据库(2009-2022)的回顾性队列研究,纳入45-60岁有绝经相关索赔且连续参保至少12个月的女性,排除双侧卵巢切除、乳腺或妇科癌症及HT禁忌者,共318621名。
主要发现
- 21.7%的女性在1年内启动系统性HT。
- 启动HT的预测因素包括较年轻年龄(aOR 2.17;95% CI 2.12-2.23)、既往子宫切除(aOR 1.98;95% CI 1.77-2.21)和局部激素使用(aOR 3.25;95% CI 3.05-3.47)。
- 肥胖(aOR 0.78;95% CI 0.75-0.81)、糖尿病(aOR 0.69;95% CI 0.66-0.72)和黑人种族(aOR 0.78;95% CI 0.68-0.89)与启动HT显著降低相关。
- 初始制剂为雌激素加孕激素(52.5%)、单用雌激素(32.4%)和单用孕激素(15.1%)。
- 中位首疗程6.6个月,38.8%在12个月时继续使用;黑人(aHR 1.52;95% CI 1.34-1.73)和西班牙裔(aHR 1.43;95% CI 1.14-1.80)停药更快,既往子宫切除(aHR 0.75;95% CI 0.68-0.83)和同时局部激素使用(aHR 0.84;95% CI 0.80-0.89)降低停药风险。
临床怎么用
- 临床应关注绝经女性HT启动率低和持续率低的问题,尤其对肥胖、糖尿病及少数族裔女性需加强个体化咨询与随访。
- 对既往子宫切除或同时使用局部激素者,可预期其HT持续可能性更高,但仍需监测长期依从性。
局限性
- 真实世界利用率可能因临床编码记录不足而更低。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE: To examine real-world patterns of systemic hormone therapy (HT) initiation and continuation among women with a diagnosis of menopause. METHODS: Using the Merative™ MarketScan® Research Databases (2009-2022), we identified women aged 45-60 years with menopause-related claims and at least 12 months of continuous enrollment. Patients with bilateral oophorectomy, breast or gynecologic cancers, or HT contraindications were excluded. Multivariable regression analyzed factors associated with HT initiation, formulation, and duration. RESULTS: Of 318,621 eligible women, 21.7% initiated systemic HT within 1 year. Predictors of HT initiation included younger age (adjusted odds ratio [aOR] 2.17; 95% CI, 2.12-2.23), prior hysterectomy (aOR 1.98; 95% CI, 1.77-2.21), and local hormone use (aOR 3.25; 95% CI, 3.05-3.47). Initiation was significantly lower among women with obesity (aOR 0.78; 95% CI, 0.75-0.81), diabetes (aOR 0.69; 95% CI, 0.66-0.72), and Black racial identification (aOR 0.78; 95% CI, 0.68-0.89). Initial formulations were estrogen plus progestogen (52.5%), estrogen-alone (32.4%), and progestogen-alone (15.1%). The median first-episode duration was 6.6 months; 38.8% of patients continued at 12 months. Black racial (adjusted hazard ratio [aHR] 1.52; 95% CI, 1.34-1.73) and Hispanic ethnic (aHR 1.43; 95% CI, 1.14-1.80) identities predicted faster discontinuation. Conversely, prior hysterectomy (aHR 0.75; 95% CI, 0.68-0.83) and concurrent local hormone use (aHR 0.84; 95% CI, 0.80-0.89) reduced discontinuation risk. CONCLUSION: Although one-fifth of women initiated systemic HT shortly after their diagnosis, low persistence and racial disparities among those who initiated reveal critical gaps in long-term menopause management. Furthermore, true real-world utilization is likely even lower due to underdocumentation in clinical coding. These findings underscore an urgent need for targeted, equitable interventions to improve treatment adherence and ensure consistent, comprehensive care for menopausal women.
引用
- Sriprasert I, Huang Y, Shoupe D, et al. Initiation and Duration of Systemic Hormone Therapy for Menopausal Symptoms. Obstet Gynecol. 2026. PMID: 42492961. doi:10.1097/AOG.0000000000006386
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。